Roivant SciencesROIV
ROIV
About: Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Employees: 750
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
242% more call options, than puts
Call options by funds: $38.5M | Put options by funds: $11.2M
6% more funds holding in top 10
Funds holding in top 10: 17 [Q4 2024] → 18 (+1) [Q1 2025]
0.25% more ownership
Funds ownership: 77.26% [Q4 2024] → 77.52% (+0.25%) [Q1 2025]
0% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 58
1% less funds holding
Funds holding: 313 [Q4 2024] → 309 (-4) [Q1 2025]
15% less repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 106
16% less capital invested
Capital invested by funds: $6.65B [Q4 2024] → $5.58B (-$1.07B) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$18
59%
upside
Avg. target
$18
59%
upside
High target
$18
59%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Douglas Tsao | 59%upside $18 | Buy Reiterated | 28 May 2025 |
Financial journalist opinion
Based on 4 articles about ROIV published over the past 30 days
Neutral
GlobeNewsWire
5 days ago
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis
BASEL, Switzerland and LONDON and NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced that they will host a live investor video conference at 1:00 PM ET on Tuesday, June 17 on brepocitinib, the unmet medical need for patients with dermatomyositis (DM) and the potential role brepocitinib could play in improving the lives of patients with DM.
Neutral
Seeking Alpha
2 weeks ago
Roivant Sciences Ltd. (ROIV) Q4 2024 Earnings Call Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV ) Q4 2024 Earnings Conference Call May 29, 2025 8:00 AM ET Company Participants Stephanie Lee - Investor Relations Matt Gline - Chief Executive Officer Richard Pulik - Chief Financial Officer Conference Call Participants Brian Cheng - JPMorgan Chase & Co. David Risinger - Leerink Partners Dennis Ding - Jefferies Yaron Werber - TD Cowen Samuel Slutsky - LifeSci Capital Yatin Suneja - Guggenheim Securities Douglas Tsao - H.C.
Negative
Zacks Investment Research
2 weeks ago
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.16.
Neutral
GlobeNewsWire
2 weeks ago
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2025, and provided a business update. Brepocitinib program progressing well with rapid enrollment in non-infectious uveitis (NIU) Phase 3 study and first patients dosed in cutaneous sarcoidosis (CS) proof-of-concept trial, with readouts expected in the first half of calendar year 2027 and second half of calendar year 2026, respectively Brepocitinib's VALOR Phase 3 study evaluating its use in patients with dermatomyositis (DM) is fully enrolled and on track for topline data readout in the second half of calendar year 2025; Roivant and Priovant will host a live conference call and webcast at 1:00 p.m.
Neutral
GlobeNewsWire
1 month ago
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025
BASEL, Switzerland and LONDON and NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 29, 2025, to report its financial results for the fourth quarter and fiscal year ended March 31, 2025, and provide a business update.
Positive
Seeking Alpha
1 month ago
Roivant Sciences: Primed For Growth With A De-Risked Pipeline
Roivant Sciences has strengthened its financial position through strategic divestitures, boasting $5.2 billion in cash and assets, enabling robust funding for its late-stage pipeline. The company's FcRn inhibitor platform, led by IMVT-1402, shows promise in autoimmune diseases, with positive clinical readouts validating its potential. Priovant's brepocitinib, targeting TYK2/JAK1 pathways, is advancing in Phase 3 trials for Dermatomyositis and Non-Infectious Uveitis, addressing significant unmet needs.
Negative
Investors Business Daily
1 month ago
Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift
Roivant Sciences is making serious changes to subsidiary Immunovant, announcing Monday a series of C-suite changes and new disease targets.
Neutral
GlobeNewsWire
1 month ago
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced next phase of growth including changes to its leadership team and the expanded development of IMVT-1402 into two new indications, SjD and CLE.
Neutral
GlobeNewsWire
1 month ago
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of Immunovant Pete Salzmann, M.D.
Positive
Investors Business Daily
2 months ago
Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.
Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval. The post Roivant, Immunovant Succeed In Phase 3.
Charts implemented using Lightweight Charts™